GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chugai Pharmaceutical Co Ltd (OTCPK:CHGCY) » Definitions » Shiller PE Ratio

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Shiller PE Ratio : 42.11 (As of May. 18, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Chugai Pharmaceutical Co Shiller PE Ratio?

As of today (2024-05-18), Chugai Pharmaceutical Co's current share price is $16.00. Chugai Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 was $0.38. Chugai Pharmaceutical Co's Shiller PE Ratio for today is 42.11.

The historical rank and industry rank for Chugai Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

CHGCY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 33.92   Med: 54.59   Max: 132.28
Current: 44.44

During the past years, Chugai Pharmaceutical Co's highest Shiller PE Ratio was 132.28. The lowest was 33.92. And the median was 54.59.

CHGCY's Shiller PE Ratio is ranked worse than
76.4% of 534 companies
in the Drug Manufacturers industry
Industry Median: 25.165 vs CHGCY: 44.44

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.151. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.38 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Chugai Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Chugai Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chugai Pharmaceutical Co Shiller PE Ratio Chart

Chugai Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 81.03 107.28 55.03 37.17 48.81

Chugai Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.52 41.09 44.38 48.81 50.97

Competitive Comparison of Chugai Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chugai Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Shiller PE Ratio falls into.



Chugai Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chugai Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=16.00/0.38
=42.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chugai Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Chugai Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.151/107.2000*107.2000
=0.151

Current CPI (Mar. 2024) = 107.2000.

Chugai Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.030 98.000 0.033
201409 0.031 98.500 0.034
201412 0.029 97.900 0.032
201503 0.037 97.900 0.041
201506 0.038 98.400 0.041
201509 0.044 98.500 0.048
201512 0.034 98.100 0.037
201603 0.039 97.900 0.043
201606 0.049 98.100 0.054
201609 0.035 98.000 0.038
201612 0.028 98.400 0.031
201703 0.050 98.100 0.055
201706 0.048 98.500 0.052
201709 0.058 98.800 0.063
201712 0.042 99.400 0.045
201803 0.080 99.200 0.086
201806 0.057 99.200 0.062
201809 0.059 99.900 0.063
201812 0.060 99.700 0.065
201903 0.096 99.700 0.103
201906 0.096 99.800 0.103
201909 0.136 100.100 0.146
201912 0.112 100.500 0.119
202003 0.145 100.300 0.155
202006 0.143 99.900 0.153
202009 0.173 99.900 0.186
202012 0.153 99.300 0.165
202103 0.133 99.900 0.143
202106 0.195 99.500 0.210
202109 0.237 100.100 0.254
202112 0.264 100.100 0.283
202203 0.338 101.100 0.358
202206 0.164 101.800 0.173
202209 0.144 103.100 0.150
202212 0.231 104.100 0.238
202303 0.167 104.400 0.171
202306 0.179 105.200 0.182
202309 0.159 106.200 0.160
202312 0.192 106.800 0.193
202403 0.151 107.200 0.151

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chugai Pharmaceutical Co  (OTCPK:CHGCY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Chugai Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Chugai Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
1-1 Nihonbashi-Muromachi 2-Chome, Nihonbashi Mitsui Tower (Reception15F), Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding Ltd, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra for hemophilia A patients and tocilizumab for treating rheumatoid arthritis and COVID-19.

Chugai Pharmaceutical Co (Chugai Pharmaceutical Co) Headlines